NCT05669014: A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM) |
|
|
| Active, not recruiting | 2 | 12 | Europe, US, RoW | Daxdilimab, HZN-7734, Placebo | Amgen | Idiopathic Inflammatory Myositis | 03/25 | 10/25 | | |
